INSY - INSYS Therapeutics, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
7.6610
-0.3890 (-4.83%)
As of 9:35AM EDT. Market open.
Stock chart is not supported by your current browser
Previous close8.0500
Open8.0600
Bid8.0500 x 1400
Ask8.1000 x 800
Day's range7.6514 - 8.1000
52-week range4.1000 - 14.0000
Volume102,519
Avg. volume632,534
Market cap565.45M
Beta2.16
PE ratio (TTM)N/A
EPS (TTM)-3.3350
Earnings date1 Aug 2018 - 6 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.20
Trade prices are not sourced from all markets
  • What You Must Know About INSYS Therapeutics Inc’s (NASDAQ:INSY) Major Investors
    Simply Wall St.6 days ago

    What You Must Know About INSYS Therapeutics Inc’s (NASDAQ:INSY) Major Investors

    Today, I will be analyzing INSYS Therapeutics Inc’s (NASDAQ:INSY) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure of a company has been found to affectRead More...

  • Florida doctor admits taking kickbacks from Insys, others
    Business Insider UK14 days ago

    Florida doctor admits taking kickbacks from Insys, others

    Dr. Michael Frey, 46, pleaded guilty on Monday in federal court in Fort Myers, Florida, to conspiring to receive kickbacks from a medical equipment provider and a pharmacy sales representative. As part of a plea agreement, he also admitted that Chandler, Arizona-based Insys paid him kickbacks in the form of fees to participate in largely bogus speaker event programs so that he would prescribe its opioid product Subsys, prosecutors said.

  • Florida doctor admits taking kickbacks from Insys, others
    Business Insider UK14 days ago

    Florida doctor admits taking kickbacks from Insys, others

    Dr. Michael Frey, 46, pleaded guilty on Monday in federal court in Fort Myers, Florida, to conspiring to receive kickbacks from a medical equipment provider and a pharmacy sales representative. As part of a plea agreement, he also admitted that Chandler, Arizona-based Insys paid him kickbacks in the form of fees to participate in largely bogus speaker event programs so that he would prescribe its opioid product Subsys, prosecutors said.

  • Associated Press19 days ago

    Minnesota sues Arizona-based opioid manufacturer

    ST. PAUL, Minn. (AP) — Minnesota's attorney general is suing an Arizona-based pharmaceutical company, alleging it illegally marketed a painkiller made from the synthetic opioid fentanyl.

  • Business Insider UK19 days ago

    Minnesota sues opioid manufacturer Insys over drug marketing

    (Reuters) - The state of Minnesota on Wednesday sued Insys Therapeutics Inc, accusing the pharmaceutical manufacturer of illegally marketing a powerful fentanyl-based pain medicine intended for cancer patients for other uses.

  • Business Insider UK19 days ago

    Minnesota sues opioid manufacturer Insys over drug marketing

    (Reuters) - The state of Minnesota on Wednesday sued Insys Therapeutics Inc, accusing the pharmaceutical manufacturer of illegally marketing a powerful fentanyl-based pain medicine intended for cancer patients for other uses.

  • INSYS Gets Negative FDA Recommendation for Pain Candidate
    Zacks26 days ago

    INSYS Gets Negative FDA Recommendation for Pain Candidate

    INSYS Therapeutics' (INSY) NDA for buprenorphine sublingual spray fails to get recommendation for approval for treating moderate-to-severe acute pain after bunionectomy from FDA advisory committee.

  • Warren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove It
    Motley Fool26 days ago

    Warren Buffett's Mentor Was Right About the Crazy Market -- and 2 Biotech Stocks Prove It

    The reaction to news from Celgene and Insys demonstrates an undeniable truth: Mr. Market can be very irrational at times.

  • This Pot Stock's First-Quarter Report Is Creating All the Wrong Buzz
    Motley Foollast month

    This Pot Stock's First-Quarter Report Is Creating All the Wrong Buzz

    This potential turnaround candidate is still headed in the wrong direction.

  • The Wall Street Journallast month

    [$$] U.S. Joins Whistleblower Suits Against Opioid Maker

    Its ex-chief executive officer, John Kapoor, and several former top executives have been charged with conspiracy to illegally distribute Subsys, a mouth-spray form of fentanyl that is approved by the Food and Drug Administration to treat cancer-related pain. Mr. Kapoor has denied wrongdoing and pleaded not guilty. Shares of Insys fell 6% on Tuesday.

  • Business Insider UKlast month

    Insys sees no change in estimated litigation costs

    The news comes a day after the U.S. Department of Justice joined a whistleblower lawsuit alleging Insys paid kickbacks to doctors. The company continues to have an ongoing dialogue with the DOJ regarding this investigation, Insys said on Tuesday. It adds firepower to the civil litigation as Insys tries to resolve a federal probe into its marketing of Subsys, a spray form of fentanyl.

  • Business Insider UKlast month

    Insys sees no change in estimated litigation costs

    The news comes a day after the U.S. Department of Justice joined a whistleblower lawsuit alleging Insys paid kickbacks to doctors. The company continues to have an ongoing dialogue with the DOJ regarding this investigation, Insys said on Tuesday. It adds firepower to the civil litigation as Insys tries to resolve a federal probe into its marketing of Subsys, a spray form of fentanyl.

  • Why Marijuana Stock Insys Therapeutics Inc. Gained 16.1% in April
    Motley Foollast month

    Why Marijuana Stock Insys Therapeutics Inc. Gained 16.1% in April

    Shares of the small-cap biotech climbed following news that the company would proceed with inhalation-based dronabinol delivery tests.

  • I Was Flat-Out Wrong About This Marijuana Stock
    Motley Foollast month

    I Was Flat-Out Wrong About This Marijuana Stock

    Insys Therapeutics continues to flounder with no rebound in sight.

  • Associated Presslast month

    Insys Therapeutics: 1Q Earnings Snapshot

    The Chandler, Arizona-based company said it had a loss of 28 cents per share. Losses, adjusted for non-recurring costs and stock option expense, came to 19 cents per share. The results matched Wall Street ...

  • Business Insider UK2 months ago

    Ex-Insys employee in U.S. opioid case sentenced to home confinement

    Natalie Perhacs, 32, was sentenced by U.S. District Judge Callie Granade in Mobile, Alabama, after pleading guilty to conspiring to pay kickbacks to the doctors to prescribe Insys' product Subsys, according to court records. The home confinement is part of a five-year period of probation imposed by Granade, who also ordered Perhacs to participate in 300 hours of community service.

  • Business Insider UK2 months ago

    Ex-Insys employee in U.S. opioid case sentenced to home confinement

    Natalie Perhacs, 32, was sentenced by U.S. District Judge Callie Granade in Mobile, Alabama, after pleading guilty to conspiring to pay kickbacks to the doctors to prescribe Insys' product Subsys, according to court records. The home confinement is part of a five-year period of probation imposed by Granade, who also ordered Perhacs to participate in 300 hours of community service.

  • Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes
    Investor's Business Daily2 months ago

    Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes

    GW Pharmaceuticals, Insys Therapeutics and Zynerba Pharmaceuticals are using cannabis-based therapies to treat a myriad of disorders, including seizures.

  • Better Marijuana Stock: 22nd Century Group vs. Insys Pharmaceuticals
    Motley Fool2 months ago

    Better Marijuana Stock: 22nd Century Group vs. Insys Pharmaceuticals

    These two biotechs are big losers so far this year. But which has the better shot at being a winner over the long run?

  • Here's Why Insys Therapeutics Inc. Tanked 17% in March
    Motley Fool2 months ago

    Here's Why Insys Therapeutics Inc. Tanked 17% in March

    A handful of threats lobbed at opioid-based drugmakers pressured shares of the pain relief specialist following a dismal earnings report.

  • 3 Most Heavily Shorted Marijuana Stocks -- Are the Naysayers Wrong?
    Motley Fool3 months ago

    3 Most Heavily Shorted Marijuana Stocks -- Are the Naysayers Wrong?

    Big bets have been placed against these marijuana stocks. But could they prove to be short-sighted?

  • Associated Press3 months ago

    5 doctors charged with taking kickbacks to tout painkiller

    Five New York City doctors were arrested Friday on charges that they accepted bribes and kickbacks from an Arizona-based pharmaceutical company to prescribe large volumes of a highly addictive painkiller. ...

  • Reuters3 months ago

    Five New York doctors charged with taking kickbacks from Insys

    Federal prosecutors on Friday brought charges against five New York doctors accused of taking kickbacks from Insys Therapeutics Inc in exchange for prescribing the company's potent fentanyl-based cancer pain medication. An indictment filed in Manhattan federal court said Gordon Freedman, Jeffrey Goldstein, Todd Schlifstein, Dialecti Voudouris and Alexandru Burducea received fees from Insys to participate as speakers in sham educational events.

  • Is Beaten-Down Marijuana Stock Insys Therapeutics a Bad-News Buy?
    Motley Fool3 months ago

    Is Beaten-Down Marijuana Stock Insys Therapeutics a Bad-News Buy?

    The biotech's continued bad news could make its current share price look like a bargain.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes